A Phase 1/2, Proof-of-Principle, Multi-Center, Open-Label, Single-Arm, Non-randomized Clinical Study to Assess Safety and Efficacy of a Tumor Vaccine Consisting of Genetically Modified Allogeneic (Human) Tumor Cells for the Expression of IL-7, GM-CSF, CD80 and CD154, in Fixed Combination With a DNA-based Double Stem Loop Immunomodulator in Patients With Advanced Renal Cell Carcinoma (ASET Study).

Trial Profile

A Phase 1/2, Proof-of-Principle, Multi-Center, Open-Label, Single-Arm, Non-randomized Clinical Study to Assess Safety and Efficacy of a Tumor Vaccine Consisting of Genetically Modified Allogeneic (Human) Tumor Cells for the Expression of IL-7, GM-CSF, CD80 and CD154, in Fixed Combination With a DNA-based Double Stem Loop Immunomodulator in Patients With Advanced Renal Cell Carcinoma (ASET Study).

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 28 Mar 2017

At a glance

  • Drugs MGN 1601 (Primary)
  • Indications Renal cell carcinoma
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Acronyms ASET
  • Sponsors Mologen
  • Most Recent Events

    • 22 Mar 2017 Planned End Date changed from 1 Nov 2017 to 1 Aug 2018.
    • 18 Sep 2014 Planned End Date changed from 1 Nov 2019 to 1 Nov 2017 as per ClinicalTrials.gov record.
    • 18 Sep 2014 Planned primary completion date changed to 1 Aug 2013 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top